Financial Contrast: Replimune Group (NASDAQ:REPL) versus Prime Medicine (NYSE:PRME)

Prime Medicine (NYSE:PRME) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Prime Medicine and Replimune Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	0	1	2	0	2.67
Replimune Group	0	0	5	0	3.00

Prime Medicine currently has a consensus price target of $21.00, indicating a potential upside of 76.47%. Replimune Group has a consensus price target of $51.60, indicating a potential upside of 186.67%. Given Replimune Group’s stronger consensus rating and higher possible upside, analysts clearly believe Replimune Group is more favorable than Prime Medicine.

Valuation & Earnings

This table compares Prime Medicine and Replimune Group’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$5.21 million	222.24	-$121.82 million	N/A	N/A
Replimune Group	N/A	N/A	-$174.28 million	($2.97)	-6.06

Prime Medicine has higher revenue and earnings than Replimune Group.

Institutional and Insider Ownership

47.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 24.3% of Prime Medicine shares are owned by insiders. Comparatively, 20.6% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Prime Medicine and Replimune Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prime Medicine	N/A	-99.16%	-51.72%
Replimune Group	N/A	-35.45%	-30.71%

Summary

Replimune Group beats Prime Medicine on 6 of the 9 factors compared between the two stocks.

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

About Replimune Group

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.